ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Change points for dynamic biomarkers in the Alzheimer's disease pathological cascade: A 30-year cohort study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Decreased Plasma IGF-1 Is Associated with Cortical Atrophy, but Not Concomitant Cerebrovascular Disease in Alzheimer's Dementia.Biomolecules · 2026Article
- Article
- Alzheimer's Disease as a Multi-Layer Network Disorder: A Systems Biology Framework Integrating Multi-Omics Mechanisms.Biomedicines · 2026Review
- Multimodal Correlates of Longitudinal Functional Decline in Behavioral Variant Frontotemporal Dementia (bvFTD).Journal of personalized medicine · 2026Article
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.Neurology · 2026Observational
- 3D quantitative MRI for cognitive performance: T1 relaxation times of the right putamen and volumes of the left hippocampus as key biomarkers.Neuroimage. Reports · 2026Article
- Autistic vs. Control Differences in MRI Scan Quality Across ABIDE-II Sites.Diagnostics (Basel, Switzerland) · 2026Article
- Superficial white matter (SWM) microstructural alterations in Parkinson's disease: a neurite orientation dispersion and density imaging and diffusion tensor imaging study.Quantitative imaging in medicine and surgery · 2026Article
- Plasma biomarker trajectories across Alzheimer's clinical onset: a 17-year prospective study.Alzheimer's research & therapy · 2026Article
- Article
- Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment.AIMS neuroscience · 2026Review
- Detection and Classification of Alzheimer's Disease Using Deep and Machine Learning.Tomography (Ann Arbor, Mich.) · 2025Article
- Article
- Lightweight Deep Learning Models with Explainable AI for Early Alzheimer's Detection from Standard MRI Scans.Diagnostics (Basel, Switzerland) · 2025Article
- Change points for dynamic biomarkers in the Alzheimer's disease pathological cascade: A 30-year cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study aimed to delineate trajectories of biomarkers-amyloid beta (Aβ), phosphorylated tau, neurodegeneration, and inflammation-and to identify change points along these trajectories.
methodsLongitudinal data were collected over 30 years from 349 cognitively unimpaired individuals enrolled in the Biomarkers for Older Controls at Risk for Dementia study. Piecewise regression models were used to identify change points in cerebrospinal fluid biomarkers, brain magnetic resonance imaging volumes, and a composite measure of global cognition.
resultsEighty-two participants progressed to mild cognitive impairment or dementia during the follow-up period. Change points were identified in years prior to clinical symptom onset: Aβ at -17.1 years, phosphorylated tau at -15.8 years, neurofilament light chain and whole-brain white matter at -11.6 years, and total ventricles at -9.7 years.
conclusionThese findings support the temporal sequence proposed by the dynamic biomarker model of Alzheimer's disease and underscore the significance of white matter degeneration as an early marker for disease progression in the pathological cascade. HIGHLIGHTS: Data were collected from 349 participants in Biomarkers for Older Controls at Risk for Dementia, a 30-year cohort study. Eighty-two participants progressed to mild cognitive impairment or dementia over an average of 11 to 12 years. Core cerebrospinal fluid biomarkers for Alzheimer's disease began to accelerate 15 to 20 years before clinical onset. Magnetic resonance imaging volumes accelerated with variations across brain structures. Volumetric changes in the white matter and ventricles preceded the hippocampus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.